Guidelines on the public health response to pretreatment HIV drug resistance
Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: second edition June 2016
![Guidelines on the public health response to pretreatment HIV drug resistance](https://iris.who.int/bitstream/handle/10665/255880/9789241550055-eng.pdf.jpg?sequence=4)
Übersicht
This publication provides guidance on the public health response to pretreatment HIV drug resistance (HIVDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) among people without prior antiretroviral (ARV) drug exposure or people with prior ARV exposure who are initiating or reinitiating first-line antiretroviral therapy (ART).
It also provides the consensus prevalence or threshold of pretreatment HIVDR to NNRTIs at which specific public health actions are triggered. This publication is a supplement to Chapter 4 of the 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (2016 WHO consolidated ARV guidelines).